Volumen: 17 # Number : 2
Publication Date : Mayo - Agosto Year: 2013
Authors: Casalini Vañek E, De Luca S, Carrera C,
Tisser L, Grana MF, Eyheremendy E.
Abstract: Multiple Myeloma (MM) is a hematologic malignancy characterized by bone marrow infiltration with neoplastic
plasma cells and monoclonal immunoglobulins production. Depending on the concentration of M protein
in urine and the percentage of plasma cells in bone marrow biopsy, it is classified from a stage of Monoclonal
Gammopathy stage of Undetermined Significance / limit, to the latent Multiple Myeloma / symptomatic and can move from a subclinical entity to the classic symptomatic
disease. In recent decades, low-dose PET-CT helpes
facilitate the detection, monitoring and evaluation of therapeutic response of MM as it combines high contrast
resolution (sensitivity) of PET with high anatomic resolution of CT, demonstrating greater sensitivity than traditional radiographic evaluation in the detection of small osteolytic lesions and similar to MRI in the detection
of diffuse disease. In turn, distinguishes between
Active Myeloma latent stages, improves the vision of extramedullary locations, and shows the difference between active and residual lesions. Due to this it is the most sensitive method to assess response to treatment.
It is the method of choice for the study of non-secretory multiple myeloma, which is proposed as a diagnostic method and in the evaluation of treatment response.
Key words: Multiple Myeloma, PET / CT, monoclonal gammopathy,
solitary plasmacytoma, non-secretory Multiple
Myeloma.
Pages : 107-112
|
